Assignee
BIOMEA FUSION INC
US·8 granted patents·13 pending applications·0 citations·filing 2021–2025
Top patents by PatentIndex Score
21 records- 0183US12116371B2Substituted pyridines as irreversible inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Oct 15, 2024·0 cites·14 claims
- 0282US2024376112A1N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOFBIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 0380US12077544B2Irreversible inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Sep 3, 2024·0 cites·20 claims
- 0476US12275739B2Inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Apr 15, 2025·0 cites·21 claims
- 0573US12215113B2Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]BIOMEA FUSION INC·Filed 2024·Granted Feb 4, 2025·0 cites·35 claims
- 0673US2025161320A1Covalent inhibitors of menin-mll interaction for diabetes mellitusBIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 0773US2024262795A1Pyrazine compounds as inhibitors of flt3BIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 0871US11945785B2Pyrazine compounds as inhibitors of FLT3BIOMEA FUSION INC·Filed 2022·Granted Apr 2, 2024·0 cites·28 claims
- 0969US12251385B2Covalent inhibitors of menin-MLL interaction for diabetes mellitusBIOMEA FUSION INC·Filed 2022·Granted Mar 18, 2025·0 cites·17 claims
- 1069US12018032B2Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interactionBIOMEA FUSION INC·Filed 2022·Granted Jun 25, 2024·0 cites·19 claims
- 1169US2024417404A1CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE AS IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTIONBIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 1268US11845753B2Inhibitors of menin-mll interactionBIOMEA FUSION INC·Filed 2021·Granted Dec 19, 2023·0 cites·20 claims
- 1362US2025312335A1Flt combination therapy for cancer and compositions thereforBIOMEA FUSION INC·Filed 2023·Application pending·0 cites
- 1462US2025353854A1Fused pyrimidine compounds as inhibitors of meninBIOMEA FUSION INC·Filed 2023·Application pending·0 cites
- 1561US2024343731A1Crystalline forms of an irreversible inhibitor of menin-mll interactionBIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 1660US2024409558A1Irreversible inhibitors of krasBIOMEA FUSION INC·Filed 2022·Application pending·0 cites
- 1759US2025066386A1Inhibitors of krasBIOMEA FUSION INC·Filed 2022·Application pending·0 cites
- 1859US2025304572A1Heterocyclic glp-1r agonistsBIOMEA FUSION INC·Filed 2025·Application pending·0 cites
- 1958US2025136558A1Pyrazine compounds as irreversible inhibitors of flt3BIOMEA FUSION INC·Filed 2022·Application pending·0 cites
- 2057US2024124467A1Fused pyrimidine compounds as inhibitors of menin-mll interactionBIOMEA FUSION INC·Filed 2021·Application pending·0 cites
- 2157US2025243207A1Synthetic methods for preparing a pyridinecarboxamide compoundBIOMEA FUSION INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BIOMEA FUSION INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →